NASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $18.39 +0.45 (+2.51%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$18.46 +0.07 (+0.38%) As of 07/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunovant Stock (NASDAQ:IMVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunovant alerts:Sign Up Key Stats Today's Range$18.02▼$18.8950-Day Range$13.92▼$18.5952-Week Range$12.72▼$34.47Volume1.44 million shsAverage Volume1.22 million shsMarket Capitalization$3.15 billionP/E RatioN/ADividend YieldN/APrice Target$36.30Consensus RatingModerate Buy Company Overview Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. Read More Immunovant Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreIMVT MarketRank™: Immunovant scored higher than 31% of companies evaluated by MarketBeat, and ranked 756th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingImmunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has only been the subject of 1 research reports in the past 90 days.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.69) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.79% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 2.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.79% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 2.61%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News SentimentN/A News SentimentImmunovant has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows4 people have added Immunovant to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $109,398.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $19,998.40 in StockJuly 12, 2025 | insidertrades.comImmunovant (IMVT) chief technology officer Stout sells $26k in stockJuly 13, 2025 | investing.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits. | Timothy Sykes (Ad)LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PTJuly 6, 2025 | msn.comImmunovant, Inc. (IMVT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comTracking Baker Brothers Portfolio - Q1 2025 UpdateJune 17, 2025 | seekingalpha.comImmunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13, 2025 | seekingalpha.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 29, 2025 | tipranks.comSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $24.77 at the beginning of the year. Since then, IMVT stock has decreased by 25.8% and is now trading at $18.39. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Thursday, May, 29th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.08. The company earned $0.16 million during the quarter. Who are Immunovant's major shareholders? Top institutional shareholders of Immunovant include Platinum Investment Management Ltd. (0.11%), Banque Pictet & Cie SA (0.07%), KLP Kapitalforvaltning AS (0.01%) and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, Frank Torti, William L Macias, Mark S Levine, Michael Geffner, Jay S Stout and Andrew J Fromkin. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings5/29/2025Today7/23/2025Next Earnings (Estimated)8/05/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMVT CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Immunovant$36.30 High Price Target$53.00 Low Price Target$17.00 Potential Upside/Downside+97.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$413.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-80.60% Return on Assets-71.89% Debt Debt-to-Equity RatioN/A Current Ratio11.16 Quick Ratio11.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.16 per share Price / Book4.42Miscellaneous Outstanding Shares171,070,000Free Float167,990,000Market Cap$3.15 billion OptionableOptionable Beta0.63 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:IMVT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.